4.7 Article

Bacteria-Targeted Combined with Photothermal/NO Nanoparticles for the Treatment and Diagnosis of MRSA Infection In Vivo

Journal

ADVANCED HEALTHCARE MATERIALS
Volume 12, Issue 20, Pages -

Publisher

WILEY
DOI: 10.1002/adhm.202300247

Keywords

bacterial infections; bacterial targeting; combination treatment; nitric oxide; photothermal therapy

Ask authors/readers for more resources

A smart antibacterial nanoplatform was developed for efficient treatment of bacteria infection using near-infrared light-controlled release and bacteria-targeted delivery of nitric oxide combined with photothermal therapy. The platform can accurately distinguish bacterial infection and efficiently deliver drugs to the infected sites. By utilizing the photothermal effect and the unique transport system of bacteria, it effectively eliminates biofilm and drug-resistant bacteria. In a myositis model of methicillin-resistant Staphylococcus aureus infection, the nanoplatform successfully eradicated inflammation and abscesses.
Currently, undeveloped diagnosis and delayed treatment of bacteria-infected sites in vivo not only expand the risk of tissue infection but are also a major clinical cause of multiple drug-resistant bacterial infections. Here, an efficient nanoplatform for near-infrared (NIR)-light-controlled release and bacteria-targeted delivery of nitric oxide (NO) combined with photothermal therapy (PTT) is presented. Using maltotriose-decorated mesoporous polydopamine (MPDA-Mal) and BNN6, a smart antibacterial (B@MPDA-Mal) is developed to combine bacterial targeting, gas-controlled release, and PTT. Utilizing bacteria's unique maltodextrin transport system, B@MPDA-Mal can accurately distinguish bacterial infection from sterile inflammation and target the bacteria-infected sites for efficient drug enrichment. Moreover, NIR-light causes MPDA to generate heat, which not only effectively induces BNN6 to produce NO, but also raises the temperature to harm the bacteria further. NO/photothermal combination therapy effectively eliminates biofilm and drug-resistant bacteria. The myositis model of methicillin-resistant Staphylococcus aureus infection is established and indicates that B@MPDA-Mal can successfully eradicate inflammation and abscesses in mice. Meanwhile, magnetic resonance imaging technology is used to monitor the treatment procedure and healing outcomes. Given the aforementioned advantages, the smart antibacterial nanoplatform B@MPDA-Mal can be used as a potential therapeutic tool in the biomedical field against drug-resistant bacterial infections.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available